Re-Gendering Depression: Risk, Web Health Campaigns, and the Feminized Pharmaco-Subject by Gardner, Paula M
Re-gendering Depression: 
Risk, Web Health Campaigns, and 
the Feminized Pharmaco-Subject 
Paula M. Gardner
Ontario College of Art and Design
Abstract: This article analyzes the textual and visual discourse of recent depres-
sion campaigns and advertisements generated by state-policy, advocacy, and
pharmaceutical organizations, drawing on the work of Anne Balsamo, Nikolas
Rose, and Paul Rabinow, among others. A variety of recent Web campaigns are
critiqued, addressing the new pharmaceutical strategy of identifying a broad
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The depression script: An introduction 
A reductionist, biopsychiatric mood logic has long been normalized in North
America and Europe (Healy, 1997; Kramer, 1993). This logic tends to assume a
single-cause model of illness, despite a concurrent reading of the body as a “com-
plex system” informed by both environmental and biological factors. Grounded
in a rationale that reduces depression to a brain disorder and overstates its threat,
popular discourses directed at consumers have helped make depression one the
most diagnosed mental disorders of all time1 (Healy, 1997). Despite its slippery
logic, the script has made a compelling public case that depression resides in sick
brains and requires biotechnical treatment. To wit, the website of National
Alliance for the Mentally Ill (NAMI) boasts that 75% of surveyed individuals
define depression as a chemical imbalance in the brain and recommends medica-
tion as treatment (NAMI, 2007e). 
This depression script is malleable. If, in the past, the script was directed pri-
marily toward women, in its latest incarnation it normalizes a broad set of dis-
tresses as symptoms of new mood illnesses, including subtypes of depression
such as dysthymia and depressions that are typified as minor, shadow, postpar-
tum, seasonal affective, pre-menstrual, et cetera. It covers a range of disorders of
eating, attention, anxiety, and panic, to name a few. Representing a new trend in
managing the health of populations, broad-spectrum illnesses are promoted to
consumers via a range of media, from websites to television advertisements to
glossy print advertisements.2 The strength of these campaigns is demonstrated by
the now-common consumer practice of using antidepressants alone to treat minor
depression, though research shows they are significantly effective only for major
depression, and in conjunction with psychotherapy.3 Problematically, these dis-
courses flatten important distinctions across depression diagnoses and constrain
consumers’ abilities to make informed treatment choices (Gardner, 2003; Healy,
2004). The conflation of major and minor depression also rationalizes the script’s
snowballing logic, which dubs symptoms as threatening a lifelong illness that
will require constant (self-) surveillance and management. The widespread sale
of pharmaceutical drugs on the Web only reinforces this tendency. 
NAMI’s discourse on depression and the research data they present mirrors
that of state health and industry groups4 (Healy, 1997). Like these other institu-
tions, NAMI defines everyday psychosocial and material phenomena, including
sexual abuse and employment, economic, and gender oppression as risks, rather
than causes. As shall be shown, these discursive ruptures make it possible for
gender to become a symptom of depression and for depression to be reified as a
gendered disease. 
This discourse relies on antiquated assumptions of gender, capitalizing on
unproven essentialist biases, countering the nature/nurture theory, and marginal-
izing social cause to re-introduce pathology into the lives of women and girls.
The script commonly symptomizes depression by everyday body and mood
behaviours, but here women, specifically, are called upon to self-scrutinize their
hormonal processes. Finally, NAMI recommends that “symptoms” be controlled
by biotechnical recovery methods, including antidepressants and short-term psy-
chotherapies; notably, the latter fits within the biopsychiatric paradigm in aiming
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to repair behaviour and cognition but ignoring the emotional, social and other
root causes of depression.
Also common to the script is NAMI’s equation of depression with national
economic depression and decreases in the gross national product, so that mood
management is referred to as “good economics. . . a return of $7 for every $1
invested” by industry (NAMI, 2007c). NAMI contends that depression diagnoses
should increase, despite the vast number of researchers who contest the script’s
slippery-slope logic that links symptoms to chronic illness. The script’s broad-
spectrum paradigm, in association with risk discourse (pointing to decreased pro-
ductivity and chronic disease), together establish a generalized risk paradigm
applicable to most individuals. Yet, pivoting on the concept of risk, this macro-
paradigm provides a mechanism whereby campaigns can logically target gen-
dered social and biological experiences as requiring surveillance for productivity
risk/symptoms. NAMI does not offer the sole example of the operation of this
complex depression script. 
Analyzing the script
Over the past decade, American pharmaceutical, health policy, and consumer
advocacy organizations have launched new campaigns designed to encourage the
diagnosis and treatment of “broad-spectrum” depression. The expanded market-
ing strategies are, it would seem, a distinctive retreat from the old-style Prozac
campaigns of the late 1980s, which targeted middle-class Caucasian females;
new campaigns seek a more egalitarian, less gendered, classed, and raced popu-
lation of potential users. In addition to the NAMI website, indicative of this shift
is the National Institute of Mental Health’s (NIMH) “Real Men” depression cam-
paign, which attempts to destigmatize male depression (NIMH, 2007a). 
These campaigns seem to redress the discourse of depression as a female dis-
order by making, and depicting, a more varied range of people “at risk.”
However, these new campaigns continue to frame gender in a binary manner
(Balsamo, 1999) that repositions it as an etiological tenet of depression. To under-
stand the manner in which these mood discourses articulate gender norms, health
consumerism, risk, and recovery, I undertake an analysis of this “depression
script” that reaches across government, industry, and consumer-advocacy materi-
als. This flexible depression script is naturalized both in drug promotions and in
consumer- and state-produced health care information for consumers. 
Having tracked pharmaceutical-ad trends, as well as consumer-advocacy dis-
courses and U.S. health campaigns, over eight years and across hundreds of sites,
in this paper I target recent depression campaigns by organizations including
NAMI, NIMH, and the American Psychiatric Association (APA), as well as
advertisements by pharmaceutical companies Eli Lilly, Forest, and Pfizer, to
illustrate the complex operations of these gendered promotional strategies and the
role played therein by discourses of risk. In particular, I draw upon the Web cam-
paigns that have emerged in the past five years; this realm is important, as it is a
much less regulated zone than other sources of promotion. Instructively, Web
pages allow for the blurring of health advertisements and promotions, which are
in fact presented as objective consumer information. As such, these Web cam-
paigns introduce questions regarding what constitutes reasonable health informa-
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tion for consumers and whether the pages’ unregulated content constrains agency
and rigorous democratic practices that require diverse, contested information. 
The method employed to analyze the visual and textual depression “promotions”
is a multidisciplinary visual-studies model, blending semiotics with poststructuralism
and feminist media and critical studies, in particular the work of Anne Balsamo. To
understand comprehensively how these broad-spectrum depression discourses oper-
ate, the paper also heeds Nikolas Rose and Paul Rabinow’s (2003) call for careful
empirical analysis of data across three key axes of biopower: knowledge of vital life
processes, power relations that take human beings as their object, and modes of sub-
jectification through which subjects work on themselves as living beings. The depres-
sion script that I identify works on all three levels. It espouses a biopsychiatric script,
creates gendered recovery subjects, and puts forth the imperative to self-manage. My
approach allows for an analysis of how visual and textual discourses together gender
mood and make a compelling case for the technological mediation of bodies.
Where numerous advocacy and media organizations and cultural critics5
have employed political-economy models to critique the creation of new diseases
by pharmaceutical companies, this analysis seeks to reveal the logic grounding
these practices in culture as well as in social institutions and industry. I examine
aspects of this logic in the pages that follow, specifically the establishment of
women as the referents for all depression scripts, the narrativization of this script
and appropriation of a feminist discourse, the tendency to encourage self-man-
agement of social trauma, and the campaign to include men within the script.
Finally, I turn to an analysis of the articulation of gender and risk. As I demon-
strate, capitalist, cultural, biopsychiatric, and neo-liberal logics together form the
broad logic of mood disorders, where risk and gender stereotypes create new
recovery subjects and new practices of biopower.
Signs of risk: Feminizing the referent of depression 
Pharmaceutical companies have historically referenced woman as the depressive
subject, hence making this the norm (Metzl, 2003). My tracking of early ads for
selective serotonin reuptake inhibitors (SSRIs)6 suggests they tended to target a
broad population of working and non-working middle-aged women through ads
in fashion and other women’s magazines, as well as TV spots placed during day-
and night-time dramas. An industry trend-setter, Eli Lilly was among the earliest
companies to advertise diverse images of working-age males. While Eli Lilly and
others have diversified their visual portfolio of subjects, whenever a single image
is employed, it is almost always a female, and a female is rarely left out of a group
shot unless the target market is male. Despite the broad and targeted marketing
directed beyond females, the visual culture of consumer Web pages instructively
positions female biology, particular women, or femininity as the primary refer-
ents signifying the risk of depression.
This conflation of women and depression has recently taken new forms. In an
image from the University of Pennsylvania health care centre (http://
pennhealth.com/health_info/tips/depression/what_causes.html) the (documented)
differences between male and female brains are employed to imply empirical
knowledge of the biological causes of female depression. Great care is taken in the
photograph to mimic the orange and red tones of PET scans, to light (unnamed)
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pieces of the female brain, and to darken the subject’s profile against a lit back-
drop to create a romantic silhouette figure. Knowledge of this subject is created
through brain rather than facial features. This idealized biotechnical subject is thus
“known” without reference to, and despite, her subjectivity. 
Pharmaceutical ads have introduced new “risk” factors to market recently
created women’s disorders that are linked to youth or aging and to a panoply of
drugs that will manage the depression likely to occur at any moment in a
woman’s life. These campaigns provide the dual message that depression, while
a risk for the general population, poses a greater risk to females. As well, the cam-
paigns reinforce women as the primary referent of depression, promoting a need
for women to undertake new practices of biopower, including auto-surveillance
and biotechnical work upon the self (Rose, 2006). 
Eli Lilly offers a “Signs of Risk” page, for example, that cites “being female”
and multitasking as two risk factors, noting that depression “might” be linked to
hormonal changes in women’s reproductive systems (Eli Lilly, 2007a). In this
way, Eli Lilly has reached to expand its female market to seniors and a success-
conscious professional female audience via “new-age” language and techniques.
Until recently, these Web pages featured images of professionally dressed
women, and the “Finding Balance” online magazine, which was contextualized
by smiling senior women and self-help recommendations for diet, exercise, and
mind-body balance to augment the pharmaco-aid of Prozac. With Lilly’s recent
attempts at market-expansion, these Web pages have morphed into pages entitled
“Balanced Living” (Eli Lilly 2007b). While “Balanced Living” pages feature a
range of gendered images, they retain a focus on feminized discourses, empha-
sizing self-care in the form of exercise and eating, self-discovery and positive
thinking. In total, Lilly’s strategic techniques identify new “at-risk” populations
within the female population, including functional women engaged in recovery
and self-care. These discourses echo mainstream health and media discourses that
prescribe life balance for working women, and provide advice on multi-tasking,
managing postpartum struggles, and aging well. It is not only middle-aged
women or seniors who are now deemed at risk. 
Depression campaigns by organizations other than pharmaceutical compa-
nies also reach out to youthful female populations. The American Psychiatric
Association’s (APA) depression page in summer 2007, for example, presented
two female teen images to signify general “depression” (American Psychiatric
Association 2007). The accompanying taglines relay the script’s theory of risk,
where untreated minor depression leads to major disorder and individuals are
called upon to self-monitor everyday moods and to “control negative thinking,”
thus reaching into a new everyday mood experience. The positioning of young
girls as referents for generalized depression triggered by troubled thinking
appears familiar to viewers, given the trend to pathologize common moods. As
well, the discourse positions women in a manner common to fashion ads, which
tend to shrink, fragment, and ridicule women in a mirror image of cultural
pathologies (Schutzman, 1999). In a similar sense, these promotions reflect our
cultural obsession with self-management by framing teen girls struggling with
emotions as aberrations in need of mood control. 
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NAMI’s depression Web pages (2007a and 2007b) for women and children
are revealing in this respect. These pages, and another specialized for policymak-
ers, repeat expert estimates of depression figures from the APA, the latter, for
example, stating that depression affects one in ten of the general population and
one in four women (NAMI, 2007c). The women’s Web page explains that “the
gender gap in susceptibility to depression most probably lies in a combination of
biological, genetic, psychological, and social factors” (NAMI, 2007b). 
While its complex script makes NAMI’s discourse appear fair, the group tar-
gets women with strategic language. The women’s Web page states, for example,
that “There appear to be important links between mood changes and reproduc-
tive health events” (NAMI, 2007b, my italics). On the children’s Web page, read-
ers learn, “With adolescence, girls, for the first time, have a higher rate of
depression than boys. This greater risk for depression in women persists for the
rest of life” (NAMI, 2007a). In this passage, the widely critiqued pathologization
of the female reproductive system is employed, paradoxically, to rationalize the
cause of depression. As well, NAMI’s discourse overstates the status of biopsy-
chiatric research. To date there is no empirical proof that hormones, genes, circa-
dian rhythms, or biochemistry specifically cause depression in women (or anyone
else). Most brain chemistry research only suggests biological cause through anti-
depressant “effect,” or as Peter Kramer contents, the drug worked, so depression
must exist (Kramer, 1993). As well, Joseph Dumit (2003) has shown that brain-
scanning technologies are ambiguous with regard to cause; visual differences
between depressed and non-depressed brains are unsurprising, in his view, and
provide no empirical evidence of biological cause. Gender thus becomes a pawn
of the script made possible by overstatements that appear scientific.
Similarly, the “Say how you feel” campaign by GlaxoSmithKlein (see
http://www.sayhowyoufeel.com) resorts to a baseline image of a Caucasian
woman as the sign of depression, but targets a clearly contemporary audience
with a cartoonish postmodern form. This ad deliberately adopts a style similar to
artist Roy Lichtenstein’s sparse, flat, critical comic forms that were intended to
parody gender and other stereotypes. Seemingly ignorant of the polysemous read-
ings of this aesthetic, GlaxoSmithKlein presumably employs the ad to attract a
market of both middle-aged and young females and to exploit, with melodramatic
effect, the “flat” affect typifying depression. The sparse visual relies on a lack of
cultural and social context, making it perhaps the ideal delivery mode for reduc-
tionist depression logic and the single-solution sale of antidepressants. 
These consumer discourses, which address a broad range of new disorders
and women across different age groups, routinely frame female subjects as
risky biological entities with disorderly symptoms requiring pharmaco-aug-
mentation. These new feminized depression discourses stress the tipping factor
of everyday risks—environmental and somatic issues, including poverty, child-
birth, work stress, and multitasking. In contrast, as we shall see, the discourse
positions men as facing risks due to work stresses and focuses on restoring
them via drug therapy. 
In promoting this new depression script to a range of women, Eli Lilly
glosses its own core logic, which ultimately blames female biology but also uses
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this biology to expand its market, creating a new discursive economy. Here, the
history of the drug “Sarafem” is instructive. As its patent for Prozac expired, Eli
Lilly launched the same drug formula as “Sarafem” in 2000 to treat pre-menstrual
dysphoric disorder (PMDD), a diagnosis feminists have disclaimed as patholo-
gizing common menstrual symptoms, and which was added illegitimately to the
American diagnostic manual of mental disorders7 (Caplan, 1995). Eli Lilly’s TV
spots for Sarafem earned it a warning letter in 2000 from the U.S. Food and Drug
Administration (FDA) for biased, unbalanced advertising that conflated milder
pre-menstrual syndrome symptoms with PMDD8. Since then, Eli Lilly has softly
marketed PMDD via a “women’s health” Web page that, even while admitting a
lack of credible proof of biological or hormonal cause, defines everyday men-
strual distresses (i.e., irritability, mood swings, tension, breast tenderness, and
bloating,) as symptoms and presents PMDD as a severe risk for reproductive-
aged women, claiming it affects 3 to 8% of women (Eli Lilly, 2007). These strate-
gies demonstrate skill in introducing new assumptions into the mood script and
embedding risk in both sex and gender, the biological and the behavioural. 
Eli Lilly’s savvy marketing strategy extends to its current online marketing
of Prozac to treat panic, bulimia, and obsessive-compulsive disorder (OCD). The
online ads interpolate young women and teens, inquiring “Are you at risk?” Each
page lists statistics that show the female youth bias of these disorders (save
OCD), admits a lack of etiological knowledge, and contextualizes the disorders
with pictures of recovered young females. Additionally, panic disorder is corre-
lated with depression, alcoholism, and substance abuse, deliberately confusing
the distinctive symptoms of each. Drug abuse is watered down as another “psy-
chological condition,” making depression seem less severe and more culturally
palatable. As well, alcohol abuse is positioned as a new female symptom requir-
ing mood surveillance. Girls, as such, become framed as keepers of postmodern,
disorderly bodies at risk for a host of unforeseen, chaotic symptoms said to
require biotechnical mediation. 
These pharmaceutical ads introduce new “risk” factors in order to market
recently created women’s disorders and drugs old and new. These campaigns pro-
vide the dual message that depression, while a risk for the general population,
poses a greater risk to females, and reinforce the need for women to undertake
auto-surveillance and biotechnical work upon the self. Diagnostic logic is linked
to self-management, for example, through consumer mood quizzes and mood-
tracking charts available at websites characterized by female referents of depres-
sion and feminized at-risk populations. Positioned as managers of their selves,
female consumers are invited to employ these overdetermined gauges, to deem
mild distresses as symptoms, and to deliver the results to medical professionals.
Matching risk and responsibility to biotechnical treatment, self-diagnostic tools
contribute to an economy in which it appears normal for vulnerable and worried
women to undertake new work upon their bodies/selves. 
Real stories: Narrativizing depression, appropriating feminism 
Paula Treichler (1992) has argued that a sense of truth is established and sus-
tained specifically by conventions of narrativizing disease, which include as rep-
resentative elements the use of narrative voice and the promulgation of images
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that normalize cultural ideas through repetition (p. 385). The formats common to
drug ads and advocacy groups such as NAMI confirm Treichler’s contention. Not
only does the depression script continue to link women with depression, but nar-
rative tales focusing on posttraumatic stress disorder (PTSD) and anxiety and
panic disorders co-opt feminist language to reify stereotypical gender roles.
These new forms of depression promotion become effective by mimicking
women’s cultural practices of telling stories to self-evaluate and drawing upon the
empowerment language of feminism. 
Intended to make readers comfortable, the narrativized format mainstreams
outdated social gender biases by cashing in on female celebrity as well as profes-
sionalism. Pfizer’s Zoloft Web ads, for example, have included well-known musi-
cian Naomi Judd’s story, which presented her in a multigenerational female family
photo accompanied by a caption that tells us that Zoloft has allowed Judd, who
suffers from an anxiety disorder, to return “back to herself once again.” Marrying
testimonials to risk, Zoloft’s Web page also provided stories from ordinary
women. “Drucilla” invited us into her self-reflection: “My life is different now—
wonderful, free. I’m back to being me. Before, I couldn’t go to concerts or. . . food
shopping. . . . But on ZOLOFT I can manage my symptoms.” Accompanied by a
grinning photo, this neo-liberalist narrative equated “taking back” control of
domestic and social roles as a “return to herself,” characterized as liberation. 
In another image on yet another Web page, a laughing woman introduced as
“Candyce” accompanied the description of her “symptoms” following rape:
trauma, sleep disruption, anxiety, panic, and terror. The discourse re-coded femi-
nist language formerly bound in a social action discourse; Candyce, we were told,
“considers herself a survivor” whose “growth” was due to Zoloft and therapy, in
addition to her “strong support system.” Following in Prozac’s footsteps, Zoloft
thus becomes a proto-feminist drug—part of a “system” that fights social vio-
lence against women one survivor’s serotonin at a time. This approach glosses the
empirical (social) cause of Candyce’s “problem,” transforming terror and sexual
violence into symptoms requiring behaviour and mood management. This dis-
course elides the social and demands that the individual survive anxiety or panic
by way of mood-altering medication—which are not, in fact, generally recom-
mended to treat these conditions (APA, 2007a).
This peculiar individualizing of depression has been a key aspect of Pfizer’s
marketing strategy. Pfizer proudly introduced Zoloft as the “first and only” drug
approved by the U.S. FDA to treat posttraumatic stress disorder, which, impor-
tantly, is the only diagnosis requiring the experience of social trauma as criteria.
One ad featured an alarming visual—an enormous black hand pursuing a ter-
rorized white pill fleeing in evident fear—exploiting biased cultural myths of the
Black rapist, while suggesting that the “problem” is the individual possessing
panic symptoms. The looming hand, fingers open to apprehend the smaller sub-
ject, becomes the primary image of perpetration, arising from the horizon with no
apparent source or reason, suggesting a chaotic environment/etiology. The
accompanying text linked terrorization to pharmaceutical treatment, asserting
“When you know more about what’s wrong, you can help make it right.” Further
causal context was housed in a banner featuring a myriad of disorders, suggest-
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ing Zoloft’s broad effectiveness and power. Finally, the text described sexual
abuse and other social causes of Post Traumatic Stress Disorder (PTSD) as “risk
factors,” contravening the diagnostic rules of the Diagnostic and Statistical
Manual of Mental Disorders itself. With sexual attack reduced to panic made
manageable by drugs, this Zoloft advertisement made violence against women
consumable and tolerable via biotechnical self-management. In keying in on our
personal desires for risk management, Zoloft’s advertisements replace social
cause with trauma and panic symptoms, effectively erasing the problems that lead
to mood disorders.9 Reflecting society’s inability to control violence against
women and fearful of this incoherence, Pfizer’s individualist, self-managed solu-
tion passes as female empowerment—the best one can do in a badly managed
world that makes women sick. 
Pfizer is not the only company to use this strategy. Eli Lilly likewise manip-
ulates and individuates female trauma, as demonstrated by its 2004 launch of
Cymbalta. This new drug technology, said to treat both the physical and mental
“pain” of depression, targets not only the brain chemical serotonin (as do Prozac
and Zoloft), but also norepinephrine, a new suspect in the causes of depression.
Cymbalta ads feature a variety of decidedly young female figures in a neon
colour scheme with postmodern appeal, as well as middle-aged Caucasian moth-
ers. A recent online ad, for example, features a mother and her children chatting
on a green lawn, articulating the calm that comes from drug enhancement. 
Employing depression-narrative practices, the Cymbalta website’s “Real
Stories” section offers video testimonials of female mood distress managed by
Cymbalta (Eli Lilly 2007c). The Web page suggests the objectivity of journalism
by using a women signified as broadcaster, silhouetted by TV screens. This
pharma-interlocutor, presented as spokesperson for science and pharmaceutical
companies, casts a dual objective-expert glean to the (obvious) biotechnical par-
adigm. The main page presents eight stacked television screens, the top row fea-
turing middle-aged Caucasian females with taglines identifying name, age, and
mood story. Below, blurred images of non-depressed middle-aged men literally
support the depressed women. 
This framing overdetermines depression as a middle-aged female disease,
juxtaposed with non-ill males who include sensitive diagnosticians and phar-
maco-treatment advocates. The site visitor is positioned to identify emotionally
with the subjective testimonials, which are cut with expert doctor advocacy of
Cymbalta and contextualized by the alleged objectivity of the broadcast medium.
The testimonials’ themes reinforce gendered stereotypes—expert/doctor as
knowledge source, brothers and husbands as knowledge purveyors, and women
as individuals who have learned to trust authorities. Most of the women did not
realize they were ill, for example, until a doctor told them, and one trusted her
doctor’s pharmacological recommendation despite disbelieving the diagnosis. In
keeping with new depression trends, the stories make social problems symptoms,
pathologizing the inability to care effectively for a child, exhaustion bred by sin-
gle parenthood, and feeling overwhelmed as the full-time caretaker of an incapac-
itated husband. The women credit Cymbalta with helping them to cope with
divorce, multitask, and manage emotions that otherwise “took over.” Through
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these persuasive narratives, Eli Lilly marries the gendered depression script—
which lauds the expert/doctor/husband/brother/researcher’s knowledge of
biopsychiatry and pathologizes social stressors as personal problems—with a
biotechnical solution. 
This consumer-marketing scheme deems any (Caucasian) middle-aged
woman, homemaker or professional, as at risk, given that her messy, postmodern
self lives in a world in which environments make women’s brains sick. Eli Lilly’s
decision to signify Cymbalta as a drug for everyday women points to the cultural
normalization of antidepressant consumption to manage a broad collection of
symptoms and risks said to threaten female moods and productivity. As well, the
Cymbalta campaign assumes a ready market exists in multitasking women—the
traditional unpaid housewife and the professional (paid) female subject equally
prepared to take responsibility for their functionality problems by choosing drug
enhancement.
Pfizer and Eli Lilly’s campaigns replicate those of NAMI and the APA liter-
ature—glossing etiology and overstating, biologizing, and gendering risk. At the
centre of these campaigns lies a requirement for women to act upon feminized
forms of risk—risks that occur throughout their lifetimes—and the promise of
salvation for the female subject who self-scrutinizes to identify broad new dis-
tresses of panic, anxiety, and trauma and accesses “expert” (albeit unstable)
depression knowledge. The discourse calls upon the will to fix the brain in order
to manage the social; as such, drugs offer the hope of coherence to the disorderly
female postmodern subject. This representation of women as subjects at risk can
be contrasted with the campaigns targeted at men. (Requests were made to repro-
duce images, refered to in the text, from the University of Pennsylvania Health
Center, and from Eli Lilly and Pfizer. Unfortunately no responses were received.
As a result, the URL links are provided instead.) 
New gendered trends: Real men
Male-targeted campaigns, as illustrated by the Prozac ad discussed below, tend to
name depression as a brain illness with unknown causes and social triggers, in
contrast with the equation of female biology with depression. Similar to femi-
nized depression marketing, the will is not blamed, but instead, subjects are beck-
oned to employ willpower to guide them to biotechnical recovery. On the website
for Prozac, for example, an African-American male is depicted dispensing the
following advice: 
It is important for you to accept that depression is a real illness—not a
weakness or a character defect. Your friend or loved one can’t “snap out
of it” and it won’t go away with time. Clinical depression is thought to
be associated with a chemical imbalance in the brain. This imbalance can
occur for no apparent reason—“out of the blue” or it can result from a
stressful triggering event such as divorce, death of a loved one, trouble
at work, or physical illness. (Eli Lilly, 2007d)
The idealization of modernist notions of dualized, gendered subjects is most
evident in NIMH’s Real Men campaigns, which are, instructively, circulated and
popularized by NAMI. The subjects depicted on the Web pages are identified as
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working men of varied races and classes, including traditionally masculine work-
ers (community protectors, including firefighters, police officers, and military
men) and culture builders (restaurateurs, art publishers, peer-counsellors).
Through these diverse representations, masculinity is re-framed broadly and
includes the “courage” to ask for help (NIMH, 2007a). Where female depression
is visually signified by hopelessness and sadness, “Real Men” are never charac-
terized as subjected. 
While there is an expansion of the types of men who are included as at risk
for depression, the discourse carefully distinguishes masculine from feminine
symptoms, referencing “scientific” research showing that depressed men present
with grumpiness, anger, underproductivity, and other “coping” mechanisms and
might abuse substances, “engage in reckless behavior” or become “angry, irrita-
ble or sometimes violently abusive.”(NIMH 2007b, p. 8). In this discursive col-
lapse, the assumed brain problem of depression reduces anti-social male
behaviours to mere symptoms. “Real men” discourse signifies an active, social
male as ideal recovery subject.10
Biology is also situated differently in these advertisements than in the ads
directed at women. Where women’s hormonal systems are specifically targeted as
a cause of depression (and social stressors as triggers), men’s hormones are not
noted as problems, and social causes are glossed over. For example, while work
stress is alluded to via the problem of underproductivity, the NIMH refrains from
addressing the depressed male as victim of any social or biological phenomena,
which might risk emasculating men with female depression discourses.11 Dressed
up as a sign of a progressive man unafraid of the stigma (read feminization) of
depression, manly “courage” is demonstrated by thwarting guilt and any aware-
ness of the emotional (and social) conditions contributing to depression. This slip-
page delegitimizes feelings of guilt commonly associated with mistreating others,
substituting instead enhanced pride achieved by biotechnical management.
We see this careful division of gender and representation in other advertising
campaigns targeting both male and female populations. Lexapro ads by Forest
Pharmaceuticals, for example, are binary gendered technologies extraordinaire.
Despite Lexapro’s apparent broad appeal, its Web pages offer a glaring main-
streaming of gendered symptoms and risks. With a splash page featuring Prozac-
like democratic appeal and expert references, Lexapro sells relief from
depression and linked anxiety symptoms to a diverse, grinning population using
the tagline “Power to enjoy life” (Forest Pharmaceuticals, 2007). Power here sig-
nifies both personal will and biotechnology’s ability to control the brain. 
As in Prozac ads, the female subjects in Lexapro advertisements are depicted
as happy to return to themselves. Here the images are telling. At the time of writ-
ing, one advertisement depicted a woman in her mirror reflection, gazing back at
reader-voyeurs as unthreatening inhabitants of the domestic/private sphere and a
young girl posing for the camera like a fashion model (Forest Pharmaceuticals
2007a). In contrast, all Lexapro men are busy: an athletic man wears a sweaty
towel on his shoulder, a giddy young man cooks dinner with his heterosexual par-
ents, and so on (Forest Pharmaceuticals, 2007b). Hormonally unstable women are
presented in evident distress (hunched body, twisted face), in polar contrast with
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the confident, repaired male images. Where Lexapro idealizes a female return to
home/coherence, for depressed men (represented as having constrained possibil-
ities, rather than sick bodies), pharmaco-repair provides a more active (sex and
social) life and is a journey toward narcissistic masculinity. In exploiting outdated
gender dualisms, Lexapro campaigns magnify the assumptions of depression risk
promotions. 
At the time of publication, Forest Pharmaceuticals replaced these dualized
images with a broad array of gendered subjects, akin to current Prozac marketing
strategies. The new campaign seeks to dress Lexapro as a gender neutral recov-
ery product but continues to link distinctive risks to males and females.
Re-gendering depression and articulating the risks
The gendering of pharmaceutical, NIMH, and NAMI depression diagnosis and
treatment across these Web pages supports Anne Balsamo’s (1999) contention
that contemporary discourses of technology in fact rely on the logic of binary
gender identity. Gender, for Balsamo, is both a cultural condition and social con-
sequence of technological deployment. As a technology itself, depression pro-
motes various biological and social attributes essential to sex and gender and
defines this collection of symptoms as a disorder that is grounded in risk but tech-
nologically manageable. Within this logic, a range of girls and women, as well as
working-age men, possess bodies/selves that require scrutiny and techno-media-
tion to ensure productivity.
Pharmaceutical companies meld gender with risk and technologies. Where
consumer advocacy and policy discourses tend to avoid visuals, pharmaceutical ads
position the docile female body as semiotic subject. Antidepressant ads routinely
signify ill and recovered bodies through visuals that demonstrate the science of
“knowing” and repairing the female, hormonally flawed body. These bodies also
illustrate the depression script’s unstable, complex model of causality. Here “natu-
ral” (biological) bodies exist in the environment, housing emotions and behaviours
that cross psychosocial and biological spheres. Different campaigns employ vary-
ing tactics to signify the complexity of emotional health as biological illness, slip-
ping from complex mind-body figures to streamlined (generally flattened) figures
of “natural” biological sickness. The logical slippages of the pharmaceutical script
work to discipline the postmodern, gendered subject/body. Reifying Balsamo’s
claims, stereotypes of the active (depressed) male subject and biologically chal-
lenged, multitasking female subject are vividly employed in pharmaceutical adver-
tising. This re-gendering is articulated to the idea of risk; these discourses accept
that while cause is unknown, (gendered) risk is knowable and manageable. 
Instructively, social theorist Ulrich Beck (1992) has characterized risk as a
byproduct of modernist institutions and industries, which create risks (e.g., envi-
ronmental pollution) that breed more risks. Subsequently, Joost Van Loon (2000)
has argued that risk articulated in mainstream (e.g., policy) discourses can never
be “known” or even predicted, but might be managed. Societies, then, continu-
ally produce risks, which are unknowable commodities as much as discourses
that breed insecurity, providing consumers with no recourse to achieve a sense of
safety. Depression risks are similarly qualified: they are bred by health manage-
ment and policy organizations and are not empirically known. 
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In popular practice, however, gauging risk is commonly undertaken to mini-
mize harm. The script feeds off this desire; it presents depression as a range of
risks that cannot be prevented but might be managed. More specifically, it deems
symptoms of gender to be knowable risks that can be managed pharmaceutically.
Where femininity becomes signified in everyday depression discourse as a risk
requiring symptom surveillance, masculinity is rarely signified as at risk, but
instead as an entity that requires bolstering. The instability of the causal logic, in
fact, creates the opening for risk logic and justifies this pre-emptive, medicative
logic. The use of this script in cultural practices (beyond social institutions) rei-
fies the reading of symptoms as risks, in turn creating more risks, more fear (than
knowledge) in consumers, and gendered practices of biopower. This move away
from the language of causality to one of risk is rife across websites that provide
information about depression, as we have seen. 
A consumer Web page named Healthy Places, for example, republishes APA
information, declaring “most environmental changes”—an unwieldy collection
of phenomena that includes death, divorce, and new motherhood—to be triggers
or ‘‘risk factors’’ of depression (APA, 1994). This discourse functions effectively
to reduce what are elsewhere termed social causes to triggers and to rename trig-
gers as risks, causing interpolated readers to fear everyday phenomena as likely
to instigate a debilitating, deadly disease. Seeking to make this glossing persua-
sive, the Web page charges that risks “afflict” poor single mothers, who “live with
loneliness, financial stress, and the unrelieved pressure of rearing children
(alone)” (APA, 1994, p. 3). In this gendered discourse, structural social problem-
atics largely impacting women are reduced to disorderly symptoms, made man-
ageable via risk-monitoring and drugs. The logical paradigms of neo-liberalism
and gender bias are inextricable here, where the APA targets women—most at
risk for social harm and neglect—to personalize hardships as symptoms requir-
ing biotechnical management. Nowhere does this discourse critique or even
acknowledge the social harm done to women as “social problems.” Instead, the
discourse and visuals focus on the personal impact of risk and women’s duty to
recognize and repair these faults via biopsychiatric technologies. Risk, in other
words, is the linchpin marrying gendered depression epistemology to biopsychi-
atric consumerism. 
A decade ago, Richard Sennett (1998) asserted that the new world of corpo-
rate re-engineering had dissolved hierarchies and brought a sense of risk requir-
ing personal character, flexibility, and the constant reinvention of self. By the
year 2000, the depression script had permeated broad consumer health dis-
courses, adding mood as a new site for personal-risk negotiation and self-reinven-
tion. Sennett’s theory is linked to the depression script through the element of
productivity; late-capitalist work environments and pharmaceutical discourses
each idealize personal thrift, streamlined behaviours, and self-management in
workers/multitaskers. The poor functioning typified by depression is easily gen-
dered and pathologized in the competitive business worlds and chaotic domestic
environments of North America. This gendering is most evident in pharmaceuti-
cal advertisements that stereotype male and female social roles and imbue them
with risk. And where depression risk is presented as bred from chaotic systems,
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biotechnical solutions (that are actually unstable and poorly understood) are made
to appear a reasonable route to improved mood, functionality, and productivity.
This unsteady linkage requires logical massaging, which is achieved by calling
up outdated gender frameworks. 
This re-framing of subjectivity through risk is the key to the biopower
achieved by depression discourses. In the discourses I have analyzed, new
depression promotions are articulated in the guise of autonomized self-scrutiny
and biotechnical recovery practices, where “responsibilized” individuals take it
upon themselves to curtail their personal risk (Dean, 1991). Replicating centuries
of gendered psychiatric bias in contemporary depression, new campaigns target
female subjects, selling sweeping new diagnoses, pathologizing common female
social and somatic experiences, and re-framing social neglect and abuse as symp-
toms. Stereotypical gendered roles are thus reconstituted in late-capitalist cloth
through gendered risk promotions. Where campaigns, for example, appeal to
male subjects as needing respite from capitalist labour demands, female subjects
are framed as responsible for career, home, and children, as well as chaotic social
problems and unstable bodies. As such, it is primarily women who require
techno-augmentation to facilitate multitasking and orderliness. 
Reviewing the economy of depression
In the new discourse on depression by NIMH, NAMI, and the APA, as well as
those of drug makers Eli Lilly and Pfizer, the presentation of broad-spectrum
depression that can afflict anyone recalls and reestablishes the feminine bias of
depression. Where “real men” are asked to acknowledge a biologically manifest
depression as active, masculine subjects, depressed women are framed as sub-
jected victims of unstable bodies. Where depressed men in recovery are signified
as gaining potency and activity, recovering women are laden with multitasking
expectations and positioned for a romantic “return” to an (allegedly) coherent
self. As a result, new forms of gendered biopower are created in new diagnoses,
new risks, and new recovery practices taken upon the self. 
Web campaigns accomplish this complex re-gendering of depression dis-
course by transforming the logic of the discourse from one of causality to one of
risk. This move is supported by the cultural lauding of biopsychiatry, which
simultaneously reduces depression to a chemical imbalance and expands the cat-
egory of who is at risk. In so doing, the market for the pre-emptive prescription
of these drugs is pried open. “Real men” and re-feminized discourses espouse
essentialized notions of gender in tandem with discourses of risk and neo-liberal-
ism, framing individuals as responsible for their symptoms. This discursive strat-
egy refigures specific individuals as managers of populations—a practice, warns
Nikolas Rose (2006) that redistributes work formerly designated to the state and
social institutions. 
As Rose claims, this new form of biopower—management through the
body—resides in practices of “translation”: acts of calculation and persuasion by
which an actor or force acts on behalf of itself or another12 (2006). Producing
new barometers for health and illness, promotional depression discourses trans-
form individuals into self-managing consumers whose improved functioning sig-
nificantly benefits society, the state, and industry, at low cost. Depression
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campaigns, then, articulate a concerning, gendered subjectivity that is essentially
linked to economic and social health and sets us on new, less-empowered courses
of citizenship. Mood-health logic makes sense only when inscribed in a neo-lib-
eral, late-capitalist model, where the consumer/citizen is defined as one whose
actions benefit the economic and social needs of self, society, and, not least,
national industrial infrastructures. 
As Emily Martin (1994) has argued, complex-systems theory presumes that
small changes cause massive instability in biological (and industry-organiza-
tional) systems and rationalizes a need for flexibility among subjects of late-cap-
italist culture. The current depression script assumes this need for flexibility and
adaptation (even augmentation) among specific depression subjects, vulnerable
to a growing set of symptoms. The script garners credulity by producing knowl-
edge both through repetition and logical ruptures—“the rich uncertainty of disor-
der” lying behind the “visible facade of the system” (Foucault, 1969, p. 76).
Because it strategically blames the environment and/or body in a complicated
(and problematic) argument, the depression script tactfully employs gender to
marry broad-spectrum diagnosis to biotechnical recovery. 
A highly constrained diagnostic economy is created through the script’s
broad-spectrum logic. Despite its illogical statements and contradictions, how-
ever, the script works effectively to interpolate consumers, as evidenced by rising
rates of minor depression and antidepressant consumption. This (unstable) script
has a seductive quality, best understood through the modes by which it transforms
social problematics into individual risk and through its creation of fissures in the
discourses that result in new knowledge and new practices upon the self. NAMI’s
script, for instance, demonstrates the slip of a gendered risk logic into the dis-
course of an organization premised on democratic values—patient empowerment
and consumer choice. The resulting new knowledge suggests the script presents
reasonable choices, even while it normalizes a binary logic of gender.
In the twenty-first century, pharmaco-technologies become the route to clar-
ified gendered roles and improved personal and work productivity. The unstable
script works to essentialize female bodies and to feminize self-analysis and mul-
titasking, while it overdetermines capitalism’s burden on men and covets male
subjects as deserving patriarchs. The discourses of NAMI, the APA, NIMH, and
big pharmaceutical companies all tacitly support this gendered framing of mood
illness, while fuelling a growing cultural intolerance for disorderly subjects and a
need to return to modernist, clarified gender roles. As such, Cymbalta, Prozac,
Sarafem, and Zoloft are best described as symptoms of a culture that is fearful of
risks—risks of illness, of low productivity, of blurred gender roles, and of post-
modern dissolution. In turn, depression reflects our culture’s insistence on self-
responsibility and symptomatizes women’s growing inability to function well
amid growing demands for self-improvement and for “flexibility” as (overbur-
dened) workers, mothers, and wives.
In depoliticizing social problems and relocating governance burdens onto
individuals, depression promotions stymie the (female) recovery subject’s possi-
bilities for citizenship. Active democratic practices of questioning, dialogue,
debate, and dissent are absent from the diagnostic economy, which instead
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restrains comprehensive information and positions female citizens, particularly,
as consumers. Within this economy, women are granted choice only among
biotechnical products, while power resides primarily with experts, doctors, and
husbands, who control the discourse. In glossing, re-framing, and invisibilizing
social problems and highlighting their negative impact on women’s functioning,
these discourses create an imperative for women to act upon themselves—a prac-
tice reinforced by the peculiar character of advanced liberal democracies: “a com-
plex of marketization, autonomization and responsibilization” (Rose, 2006, p. 4). 
Depression promotions and advertisements illustrate the deep gender biases
that still reside in culture and the extent to which these are exploitable—in this
case, hailing distressed women as discursive subjects who should take personal
responsibility for broad social dysfunction. Worse yet, the diagnostic economy
relieves citizens, particularly men, of the burdens they should shoulder for facil-
itating structural bias and perpetrating violence against women in the forms of
neglect, abuse, and rape. Following the logic of the diagnostic economy and the
cycle it perpetuates, women, who are environmentally most “at risk,” are posi-
tioned to carry increasing social burdens until eventually we only “function” with
pharmaco-augmentation. 
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Notes
1. As I have argued elsewhere, the script houses a number of overdetermined logics. Assuming that
depression is a biological brain problem and reading small distresses as symptoms, the script rou-
tinely suggests that minor depression will grow into major, and major into chronic depression, if
untreated. These claims are not grounded in scientific research and are in fact contested by a range
of researchers, but they are nevertheless circulated routinely as the facts of depression in what can
be described as a slippery-slope logic (Gardner, 2003).
2. Twenty-one percent of American Internet users have searched for information on-line regarding
depression, anxiety, or other mental health issues, according to the Pew Internet and American
Life Project (Fox & Fallows 2003). Given that middle- and upper-income individuals typically
have Web access, one can assume that depression Web information is a major source of mood
knowledge for Web users.
3. Elkin, Shea, Watkins, Imber, Sotsky, Collins, et al. (1989) have authored the most comprehensive
study to date comparing the effect upon minor depression of antidepressants, psychotherapy,
placebos, and doing nothing at all. They found no difference in the impact of any of these treat-
ments. The importance of this study is further discussed in Gardner (2003).
4. These include the National Institute of Mental Health (NIMH), Healthy People 2010, and the
National Depression Screening Day (NDSD), the latter being a government-run coalition of
industry, government, health, and advocacy groups.
5. These critics include critical scholars, advocacy groups, mainstream journalists, scientific
experts, and journalists.
6. Prozac, Zoloft, Effexor, and other such antidepressants are selective serotonin reuptake inhibitors,
which are said to be smart drugs targeting serotonin problems in the brain. Pharmaceutical com-
panies admit, however, they are unsure how the drugs work, why they work on some people and
not others, and why they cause some people to become more deeply depressed or even violent.
7. Premenstrual Dysphoric Disorder (PMDD) was added by the editor of the Diagnostic and
Statistical Manual of Mental disorders, Fourth Revision (The DSM –IV) appendix as a diagnosis,
despite lack of support from the PMDD working group. According to Paula Caplan (1995), work-
ing-group members found the diagnostic data supporting PMDD to be flawed and inconclusive.
Notably, Prozac is not authorized for PMDD in Europe, as the diagnosis is not listed in the
European diagnostic manual (the ICD).
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8. See http://www.pharmcast.com/WarningLetters/November2000/EliLilly1100.htm.
9. Note that Pfizer has, since August 2007, replaced the Zoloft consumer pages including the pages on
PTSD, Anxiety Disorder and Panic Disorder, with a disclaimer regarding the suicidal impact asso-
ciated with Zoloft use in children, adolescents, and adults. This is likely due in part to Pfizer’s ongo-
ing legal and regulatory problems. For example, a 2004 US FDA (Federal Drug Administration)
ruling required Pfizer to place a “black box” warning noting the suicidal risks associated with Zoloft
consumption. That same year, a citizen’s consumer protection lawsuit was filed against Pfizer for
their failure to abide by the FDA ruling in print ads, and various lawsuits have since been wielded
against the drug company, alleging Zoloft was the cause of suicide in adult and child cases.
Some of the referred to Zoloft images and text can be accessed by searching Zoloft.com on the
web archive (http://web.archive.org). (Search Zoloft and take July 6, 2007 link.) To date, the
archive website has not yet banked the PTSD, anxiety, and panic disorder pages. In the past, these
pages were accesible by following links to the diagnoses (PTSD, Anxiety Disorer, and Panic
Disorder) from zoloft.com.
10. This move to promote a different type of male depression has carved a path for other discourses
in recent years on male mental illness and for pharmaceutical ad campaigns that target men with
symptoms of obsessive-compulsive disorder, bulimia, and panic disorder, among other diagnoses.
11. Interestingly, this campaign sidesteps research on male depression conducted at the Mayo Clinic,
as reported in an article widely available online. Like the “Real Men” campaign, the article
describes depression as having psychosocial (risk) factors that lead to brain disease, dualizes male
and female symptoms, and symptomatizes anti-social male behaviours. However, the article
clearly articulates that men “may be more vulnerable than women to depression triggered by job-
related stresses” that include powerlessness at work, lack of job security or good communication
skills, performance harassment, and underpaid employment (MayoClinic.com, 2007). The article
plainly contends “a profound loss of identity, status and dignity” increases men’s risk of depres-
sion (MayoClinic.com, 2007).
12. Rose takes this term from the work of Callon and Latour (1981).
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